Cargando…
FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group
BACKGROUND: Factor VIII (FVIII) inhibitor diagnosis and surveillance in Indonesia are challenging owing to geographic conditions and the lack of laboratory facilities nationwide for inhibitor assays. This study aimed to determine the prevalence of FVIII inhibitors in children diagnosed with hemophil...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812731/ https://www.ncbi.nlm.nih.gov/pubmed/36535639 http://dx.doi.org/10.5045/br.2022.2022153 |
_version_ | 1784863793946296320 |
---|---|
author | Chozie, Novie Amelia Gatot, Djajadiman Sudarmanto, Bambang Susanah, Susi Purnamasari, Rini Widjajanto, Pudjo Hagung Nugroho, Susanto Rasiyanti, Olga Puspitasari, Dian Riza, Muhammad Larasati, Maria Christina Shanty Adiyanti, Sri Suryo Saraswati, Made Citra Primacakti, Fitri |
author_facet | Chozie, Novie Amelia Gatot, Djajadiman Sudarmanto, Bambang Susanah, Susi Purnamasari, Rini Widjajanto, Pudjo Hagung Nugroho, Susanto Rasiyanti, Olga Puspitasari, Dian Riza, Muhammad Larasati, Maria Christina Shanty Adiyanti, Sri Suryo Saraswati, Made Citra Primacakti, Fitri |
author_sort | Chozie, Novie Amelia |
collection | PubMed |
description | BACKGROUND: Factor VIII (FVIII) inhibitor diagnosis and surveillance in Indonesia are challenging owing to geographic conditions and the lack of laboratory facilities nationwide for inhibitor assays. This study aimed to determine the prevalence of FVIII inhibitors in children diagnosed with hemophilia A (HA) in Indonesia. METHODS: A cross-sectional study was conducted in 12 hospitals in eight provinces of Indonesia between 2020 and 2021. Factor VIII inhibitor screening was performed in a central hemostasis laboratory for all children with HA (≤18 yr) who had received a minimum of 10 exposure days to clotting factor concentrates. The FVIII inhibitor titer was determined using the Bethesda assay. RESULTS: Children (388) were enrolled in this study, including 219 (56.4%), 131 (33.8%), and 38 (9.4%) with severe, moderate, and mild HA, respectively. The prevalence of children who developed FVIII inhibitors was 37 out of 388 (9.6%). Factor VIII inhibitors were found in 25/219 (11.4%) severe, 11/131 (8.3%) moderate, and 1/38 (2.6%) children with mild HA. Thirteen children had low-titer inhibitors and 24 had high-titer inhibitors, with a median of 9.44 (1.48‒412.0) Bethesda Units. Among 13 children with low-titer inhibitors, eight underwent a confirmation test, of which five tested negative and were classified as transient. A significant difference in annual joint bleeding rate was found between patients with low and high inhibitor titers and those without inhibitors (P<0.001). CONCLUSION: Factor VIII inhibitor prevalence in Indonesia was relatively low. However, the risk factors that may contribute to FVIII inhibitor development among Indonesian patients require further study. |
format | Online Article Text |
id | pubmed-9812731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis |
record_format | MEDLINE/PubMed |
spelling | pubmed-98127312023-01-30 FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group Chozie, Novie Amelia Gatot, Djajadiman Sudarmanto, Bambang Susanah, Susi Purnamasari, Rini Widjajanto, Pudjo Hagung Nugroho, Susanto Rasiyanti, Olga Puspitasari, Dian Riza, Muhammad Larasati, Maria Christina Shanty Adiyanti, Sri Suryo Saraswati, Made Citra Primacakti, Fitri Blood Res Original Article BACKGROUND: Factor VIII (FVIII) inhibitor diagnosis and surveillance in Indonesia are challenging owing to geographic conditions and the lack of laboratory facilities nationwide for inhibitor assays. This study aimed to determine the prevalence of FVIII inhibitors in children diagnosed with hemophilia A (HA) in Indonesia. METHODS: A cross-sectional study was conducted in 12 hospitals in eight provinces of Indonesia between 2020 and 2021. Factor VIII inhibitor screening was performed in a central hemostasis laboratory for all children with HA (≤18 yr) who had received a minimum of 10 exposure days to clotting factor concentrates. The FVIII inhibitor titer was determined using the Bethesda assay. RESULTS: Children (388) were enrolled in this study, including 219 (56.4%), 131 (33.8%), and 38 (9.4%) with severe, moderate, and mild HA, respectively. The prevalence of children who developed FVIII inhibitors was 37 out of 388 (9.6%). Factor VIII inhibitors were found in 25/219 (11.4%) severe, 11/131 (8.3%) moderate, and 1/38 (2.6%) children with mild HA. Thirteen children had low-titer inhibitors and 24 had high-titer inhibitors, with a median of 9.44 (1.48‒412.0) Bethesda Units. Among 13 children with low-titer inhibitors, eight underwent a confirmation test, of which five tested negative and were classified as transient. A significant difference in annual joint bleeding rate was found between patients with low and high inhibitor titers and those without inhibitors (P<0.001). CONCLUSION: Factor VIII inhibitor prevalence in Indonesia was relatively low. However, the risk factors that may contribute to FVIII inhibitor development among Indonesian patients require further study. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022-12-31 2022-12-31 /pmc/articles/PMC9812731/ /pubmed/36535639 http://dx.doi.org/10.5045/br.2022.2022153 Text en © 2022 Korean Society of Hematology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Chozie, Novie Amelia Gatot, Djajadiman Sudarmanto, Bambang Susanah, Susi Purnamasari, Rini Widjajanto, Pudjo Hagung Nugroho, Susanto Rasiyanti, Olga Puspitasari, Dian Riza, Muhammad Larasati, Maria Christina Shanty Adiyanti, Sri Suryo Saraswati, Made Citra Primacakti, Fitri FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group |
title | FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group |
title_full | FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group |
title_fullStr | FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group |
title_full_unstemmed | FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group |
title_short | FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group |
title_sort | fviii inhibitor surveillance in children with hemophilia a in indonesia: a report from the indonesian pediatric hematology-oncology working group |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812731/ https://www.ncbi.nlm.nih.gov/pubmed/36535639 http://dx.doi.org/10.5045/br.2022.2022153 |
work_keys_str_mv | AT chozienovieamelia fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT gatotdjajadiman fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT sudarmantobambang fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT susanahsusi fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT purnamasaririni fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT widjajantopudjohagung fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT nugrohosusanto fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT rasiyantiolga fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT puspitasaridian fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT rizamuhammad fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT larasatimariachristinashanty fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT adiyantisrisuryo fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT saraswatimadecitra fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup AT primacaktifitri fviiiinhibitorsurveillanceinchildrenwithhemophiliaainindonesiaareportfromtheindonesianpediatrichematologyoncologyworkinggroup |